News and Reports
-
Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare
18 December 2024Download -
Neurelis Enters $208 Million Agreement to Monetize Intravail Royalties
14 November 2024Download -
Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors
30 October 2024Download -
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
25 October 2024Download -
OneSource, the Group’s Spec Pharm CDMO, receives equity commitments of INR 8,010 mn (USD 95 mn) from marquee investors at a pre-money equity valuation of USD 1.65 bn
16 October 2024Download -
Beckman Coulter and SphingoTec Partner to Improve Kidney Health Assessment in Critical Care
9 October 2024Download -
C-Ray Therapeutics Announced Approval of the First Radiation Safety License for Its Chengdu Facility in China
27 September 2024Download -
SWIXX Signs Agreement With Krystal Biotech For VYJUVEK® Gene Therapy
25 September 2024Download -
"Leading Mobile Healthcare Company" FANGZHOU JIANKE (06086) to Form Strategic Partnership with Tencent to jointly promote the upgrade of internet healthcare intelligence.
20 September 2024Download -
Upstream Bio Announces Oral Presentation of New Data from a Phase 1b Multiple Ascending Dose Trial of Verekitug (UPB-101) in Adults with Asthma at the European Respiratory Society Congress
9 September 2024Download -
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
9 September 2024Download -
SphingoTec Closes €5M Series C to Accelerate Market Development and Financial Growth with Innovative Biomarkers
8 August 2024Download -
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-01, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-01, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Pso
29 July 2024Download -
Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer
24 July 2024Download -
Genalyte - FDA Clears Silicon Chip Based Blood Test
22 July 2024Download -
Johnson & Johnson strengthens pipeline to lead in atopic dermatitis with acquisition of Yellow Jersey Therapeutics
11 July 2024Download -
SWIXX BioPharma formally closes the deal with Biopas, expanding to Latin America
4 July 2024Download -
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
27 June 2024Download -
Transaktion HBM-Portfoliounternehmen Yellow Jersey geht an Johnson & Johnson
28 May 2024Download -
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-specific Antibody for the Treatment of Atopic Dermatitis
28 May 2024Download -
Swixx BioPharma Expands to Latin America Through a Strategic Acquisition and Combination with Biopas
22 May 2024Download -
Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline
9 May 2024Download -
Karius Raises $100M Co-Led by Khosla Ventures, 5AM Ventures and Gilde Healthcare, to Expand Access to Advanced Genomic Diagnostics in Infectious Disease, Addressing Antimicrobial Resistance Crisis
2 May 2024Download -
NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression
15 April 2024Download -
Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team
2 April 2024Download